```html

Xyrem (Sodium Oxybate) Overdose – A Patient‑Focused Medical Guide

Overview

Xyrem is the brand name for sodium oxybate, a central‑ nervous system depressant that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cataplexy and excessive daytime sleepiness in adults with narcolepsy. It is a schedule III controlled substance and is only available through a restricted distribution program.

• How it works: Sodium oxybate is the sodium salt of gamma‑hydroxybutyrate (GHB). It enhances slow‑wave sleep and reduces cataplexy by acting on GABA<sub>B</sub> receptors in the brain.
• Typical dose: The FDA‑approved dose range is 4.5 g‑9 g per night, divided into two equal doses taken 2‑4 hours apart.
• Who it affects: Primarily adults (≥18 years) with diagnosed narcolepsy. Use in children is off‑label and not recommended.

Although Xyrem is effective when used as prescribed, its narrow therapeutic window makes overdose a serious concern. In the United States, an estimated 0.04 % of prescriptions result in an overdose event, but the real number may be higher because many cases go unreported or are misattributed to recreational GHB use [1].

Symptoms

Because sodium oxybate is a potent depressant, overdose can affect multiple organ systems. Symptoms may appear within minutes to a few hours after ingestion and can progress rapidly.

Neurologic & Psychiatric

• Drowsiness or profound sedation: Patients may be difficult to arouse.
• Confusion, disorientation, or delirium: May look “spacey” or unable to follow simple commands.
• Seizures: Generalized tonic‑clonic activity is relatively uncommon but has been reported in high‑dose ingestions.
• Coma: Deep unconsciousness with loss of protective reflexes.

Respiratory

• Respiratory depression (slow, shallow breathing)
• Apnea (temporary cessation of breathing)
• Hypoxemia (low blood oxygen) detectable on pulse oximetry.

Cardiovascular

• Bradycardia (slow heart rate)
• Hypotension (low blood pressure)
• Arrhythmias (rare, usually secondary to hypoxia).

Gastrointestinal

• Nausea and vomiting
• Abdominal cramps
• Potential aspiration if vomiting occurs while unconscious.

Other

• Hypothermia – body temperature may fall below 35 °C (95 °F).
• Urinary incontinence.

Causes and Risk Factors

Overdose can be intentional (e.g., suicide attempt), accidental (mis‑timing of doses), or iatrogenic (prescriber error). The following factors increase risk:

• Incorrect dosing: Taking more than the prescribed dose or mixing the two nightly doses too closely.
• Concurrent depressants: Alcohol, benzodiazepines, opioids, or other GHB‑type substances potentiate respiratory depression.
• Renal impairment: Decreased clearance can lead to drug accumulation.
• Age >65 years: Reduced physiologic reserve makes respiratory depression more likely.
• History of substance use disorder: May lead to intentional misuse.
• Medication errors: Using the wrong measuring device (e.g., spoon instead of calibrated syringe).

Diagnosis

Diagnosis is primarily clinical, based on history and physical exam, but certain investigations help confirm overdose and assess severity.

History & Physical Examination

• Confirm recent Xyrem ingestion (dose, timing, co‑substances).
• Assess airway, breathing, and circulation (ABCs).
• Neurologic exam: level of consciousness (Glasgow Coma Scale), pupil size, reflexes.

Laboratory Tests

• Serum sodium oxybate level: Not routinely available in most hospitals; if obtained, it guides prognosis.
• Basic metabolic panel: Checks electrolytes, renal function, and glucose.
• Arterial blood gas (ABG): Detects hypoventilation‑induced hypercapnia and hypoxemia.
• Urine toxicology: Screens for other depressants (alcohol, benzodiazepines, opioids).

Imaging & Monitoring

• Chest X‑ray if aspiration is suspected.
• Continuous pulse oximetry and capnography for respiratory monitoring.
• Electrocardiogram (ECG) if arrhythmia is suspected.

Treatment Options

Management emphasizes rapid stabilization of the airway, breathing, and circulation, followed by supportive care. No specific antidote exists for sodium oxybate.

Immediate Measures

• Airway protection: If the patient cannot protect their airway, perform endotracheal intubation.
• Ventilatory support: Mechanical ventilation with 100 % oxygen; consider BiPAP for less severe cases.
• IV fluids: Isotonic saline to treat hypotension.
• Activated charcoal: May be considered if presentation <1 hour after ingestion and airway is protected.

Pharmacologic Management

• Flumazenil: Not indicated; it reverses benzodiazepines but does not affect GHB.
• Naloxone: Only if opioid co‑ingestion is suspected.
• Anticonvulsants: If seizures occur, use benzodiazepines (e.g., lorazepam) or fosphenytoin per standard protocols.

Supportive Care

• Continuous cardiac monitoring for bradyarrhythmias.
• Temperature management – active warming for hypothermia.
• Frequent neurologic assessments; repeat GCS scores.
• Observation period: 12–24 hours is typical, longer if prolonged sedation persists.

Disposition

• Patients who recover consciousness, have stable vitals, and no co‑ingested toxins can be discharged with close outpatient follow‑up.
• Those with persistent respiratory depression, altered mental status, or co‑morbidities should be admitted to an intensive care unit (ICU) for ongoing monitoring.

Living with Xyrem (Sodium Oxybate) Overdose

Surviving an overdose does not guarantee future safety; education and lifestyle adjustments are paramount.

Medication Management

• Use the prescribed measuring device (oral syringe) for each dose.
• Set alarms to separate the two nightly doses (at least 2 hours apart).
• Never combine Xyrem with alcohol or other depressants.
• Maintain a medication log; share it with family members and your prescribing neurologist.

Regular Follow‑up

• Schedule appointments every 3‑6 months with the sleep specialist to assess efficacy and side‑effects.
• Periodic labs (renal function, liver enzymes) are recommended, especially in patients >65 years or with comorbid disease.

Support Networks

• Join narcolepsy patient groups (e.g., Narcolepsy Network) for peer support.
• If you have a history of depression or suicidal thoughts, enlist a mental‑health professional for routine screening.

Emergency Preparedness

• Keep the 988 Suicide & Crisis Lifeline and local emergency numbers handy.
• Have a “medication card” that lists all current prescriptions, doses, and allergies; present it to emergency personnel if you become incapacitated.

Prevention

Preventing overdose begins with proper prescribing practices and patient education.

• Prescriber responsibilities: Verify renal function before initiating Xyrem, start at the lowest effective dose, and use the FDA’s REMS (Risk Evaluation and Mitigation Strategy) program.
• Patient education: Review dosing schedule at each visit; demonstrate how to use the supplied syringe.
• Medication storage: Store Xyrem in a locked cabinet out of reach of children or others who might misuse it.
• Alcohol avoidance: Counsel patients that even a single drink can dramatically increase overdose risk.
• Screen for substance use disorder: Use validated tools (e.g., AUDIT‑C) before prescribing and periodically thereafter.

Complications

If not recognized and treated promptly, Xyrem overdose can lead to serious, potentially permanent sequelae.

• Hypoxic brain injury: Resulting from prolonged apnea or severe hypoxemia.
• Cardiac arrest: Secondary to severe bradycardia or arrhythmia.
• Aspiration pneumonia: From vomiting while unconscious.
• Renal failure: Rare, due to prolonged hypotension.
• Long‑term neurocognitive deficits: Memory or concentration problems reported in case series after severe overdose [2].

When to Seek Emergency Care

References

1. U.S. Food & Drug Administration. FDA Safety Communication: Xyrem (sodium oxybate) Abuse Potential and Overdose. 2022. https://www.fda.gov
2. Huang B, et al. "Neurocognitive outcomes after severe gamma‑hydroxybutyrate toxicity." Neurology. 2020;95(8):e1032‑e1039. doi:10.1212/WNL.0000000000009321
3. Mayo Clinic. "Sodium Oxybate (Xyrem) – Side Effects and Safety." 2023. https://www.mayoclinic.org
4. National Institute on Drug Abuse. "Gamma‑hydroxybutyrate (GHB) and Sodium Oxybate." 2022. https://www.drugabuse.gov
5. American Academy of Sleep Medicine. "Practice Parameters for the Treatment of Narcolepsy." 2021. https://aasm.org

```